loading

Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten

pulisher
Jun 17, 2025

Trevi Therapeutics Stockholders Approve Key Amendments - TipRanks

Jun 17, 2025
pulisher
Jun 14, 2025

Leerink Partnrs Issues Optimistic Estimate for TRVI Earnings - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Oppenheimer Raises Price Target for Trevi Therapeutics by $3 - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Acquires Shares of 14,059 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - Eastern Progress

Jun 09, 2025
pulisher
Jun 09, 2025

WilmerHale Advises Trevi Therapeutics, Inc. in $115 Million Public Offering - WilmerHale

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Advisers LP Invests $66,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Trevi Therapeutics (NASDAQ:TRVI) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Closes Public Offering - MarketScreener

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritte - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares | TRVI Stock News - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Secures Massive $115M Funding: Investors Rush to Back Chronic Cough Treatment Developer - Stock Titan

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Announces Pricing of $100 Million Underwritte - GuruFocus

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Sold by BNP Paribas Financial Markets - Defense World

Jun 05, 2025
pulisher
Jun 05, 2025

Ameriprise Financial Inc. Acquires 63,067 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 05, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Prices $100 Mln Public Offering Of Common Stock - Nasdaq

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Announces Public Offering Pricing - TipRanks

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics IncExpects Cash Resources To Fund Operations Into 2029 - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock - Eastern Progress

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Announces Proposed Public Offering of Common Stock - Longview News-Journal

Jun 04, 2025
pulisher
Jun 04, 2025

Trevi Therapeutics Prices $100 Million Common Stock Offering - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Buys 9,589 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 04, 2025
pulisher
Jun 04, 2025

Biotech Trevi Therapeutics Secures Major $100M Financing Through Stock Offering - Stock Titan

Jun 04, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics Announces Pricing Of $100 Million Underwritten Offering Of Common Stock - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

H.C. Wainwright maintains Trevi Therapeutics stock rating following trial results - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Oppenheimer Boosts Trevi Therapeutics (TRVI) PT to $23, Cites Positive Haduvio Trial Results - Insider Monkey

Jun 03, 2025
pulisher
Jun 03, 2025

Stifel reiterates buy rating for Trevi Therapeutics stock after study results - Investing.com Canada

Jun 03, 2025
pulisher
Jun 03, 2025

Oppenheimer Adjusts Price Target on Trevi Therapeutics to $23 From $20, Maintains Outperform Rating - marketscreener.com

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics stock soars to 52-week high of $7.43 By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics launches $100 million stock offering By Investing.com - Investing.com South Africa

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics (NASDAQ:TRVI) Given “Buy” Rating at D. Boral Capital - Defense World

Jun 03, 2025
pulisher
Jun 03, 2025

Trevi Therapeutics stock soars to 52-week high of $7.43 - Investing.com India

Jun 03, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Terminates ATM Prospectus with Leerink - TipRanks

Jun 02, 2025
pulisher
Jun 02, 2025

Oppenheimer raises Trevi Therapeutics stock price target to $23 By Investing.com - Investing.com UK

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics launches $100 million stock offering - Investing.com Australia

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Plans $100 Million Stock Sale; Shares Sliding in After-Hours Trade - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Oppenheimer Boosts Trevi Therapeutics (TRVI) Price Target to $23 | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics (TRVI) Receives "Buy" Rating from D. Boral Capital | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Announces Proposed Public Offering Of Common Stock - marketscreener.com

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics (TRVI) Launches $100M Public Offering | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Announces Proposed Public Offering of Common Stock | TRVI Stock News - GuruFocus

Jun 02, 2025
pulisher
Jun 02, 2025

Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients - Benzinga

Jun 02, 2025
pulisher
Jun 02, 2025

trevi therapeutics reports positive results from phase 2b cough trial By Investing.com - Investing.com Australia

Jun 02, 2025
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):